(Bloomberg) — A new startup called Ovax Inc. has raised $10 million to develop a vaccine to prevent fentanyl deaths, aiming to commercialize academic research that prevents the drug from reaching the brain. The startup has licensed intellectual property from researchers at the University of Houston who have successfully tested a fentanyl vaccine in rats. Ovax, which officially launches this week, plans to begin the first human trials of the vaccine early next year. If successful, the vaccine will block users of fentanyl from getting high or overdosing from the drug. “The science is there,” said JR Rahn, the startup’s co-founder. “It just takes someone to be persistent” to bring it to marke
Hence then, the article about startup s fentanyl vaccine aims to block drug s highs overdoses bnn bloomberg was published today ( ) and is available oncanadian news today ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details Finally We wish PressBee provided you with enough information of ( Startup’s ‘Fentanyl Vaccine’ Aims to Block Drug’s Highs, Overdoses – BNN Bloomberg )